Compare Merck & Co., Inc. (MRK) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Shell PLC — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Shell PLC trades at $100.15 (market cap $284.34B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Shell PLC pays the higher dividend (3.12%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Shell PLC for 90 Days on average.
| MRK | SHEL | |
|---|---|---|
Market Cap | $351.28B | $284.34B |
Volume | 7,969,665 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $156.43 | $100.20 |
52-Week Low | $82.49 | $70.31 |
Typical Hold Time | 98 Days | 90 Days |
Enterprise Value | $398.04B | $326.04B |
Dividend Yield | 2.39% | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Shell (SHEL) trades at $100.56, up 3.83% today, approaching its 52-week high. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The stock shows bullish technical signals, supported by strong cash flow and a 61.5% analyst buy rating. Key developments include the LNG Canada Phase 2 expansion, doubling export capacity, and new carbon capture deals, highlighting strategic growth in energy transition assets.
Outlook remains positive with valuation metrics like P/E of 11.08 and EV/EBITDA of 4.8 suggesting room for upside toward the $102.53 consensus target. Risks include volatile oil prices and execution challenges in new projects, but robust LNG demand and portfolio optimization provide a solid foundation for investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
